603 related articles for article (PubMed ID: 19934817)
21. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
22. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE
Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
[TBL] [Abstract][Full Text] [Related]
23. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
[TBL] [Abstract][Full Text] [Related]
24. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
25. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
28. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
30. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
Jonas JB; Tao Y; Rensch F
Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
[No Abstract] [Full Text] [Related]
32. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
[TBL] [Abstract][Full Text] [Related]
33. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
34. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
35. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
Zweifel SA; Engelbert M; Khan S; Freund KB
Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
[TBL] [Abstract][Full Text] [Related]
36. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M; Zweifel SA; Freund KB
Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
[TBL] [Abstract][Full Text] [Related]
37. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
[TBL] [Abstract][Full Text] [Related]
39. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration.
Furino C; Ferrara A; Cardascia N; Besozzi G; Alessio G; Sborgia L; Boscia F
J Cataract Refract Surg; 2009 Sep; 35(9):1518-22. PubMed ID: 19683147
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
